陽普醫療(300030.SZ):公司董事長、總經理鄧冠華被立案調查、實施留置
格隆匯7月8日丨陽普醫療(300030.SZ)公佈,公司於近日收到珠海市監察委員會簽發的《立案通知書》和《留置通知書》,公司董事長、總經理鄧冠華先生被立案調查、實施留置。
截至公吿日,公司尚未知悉調查的進展及結論。公司其他董事、高級管理人員及監事均正常履職,董事會依法履行相關職責,生產經營管理情況正常。公司將持續關注上述事項的後續進展情況,對相關工作進行妥善安排,並按照有關法律、法規的規定和要求,及時履行信息披露義務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.